Suppr超能文献

随访功能分级和 6 分钟步行距离可预测肺动脉高压的长期生存。

Follow-Up Functional Class and 6-Minute Walk Distance Identify Long-Term Survival in Pulmonary Arterial Hypertension.

机构信息

Department of Pulmonary and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, 9500 Euclid Avenue, A90, Cleveland, OH, 44195, USA.

United Therapeutics, Durham, NC, USA.

出版信息

Lung. 2020 Dec;198(6):933-938. doi: 10.1007/s00408-020-00402-w. Epub 2020 Nov 19.

Abstract

PURPOSE

Guidelines recommend specific treatment goals for pulmonary arterial hypertension (PAH) patients: functional class I or II, 6-min walk distance (6MWD) ≥ 380 to 440 m, normal natriuretic peptide levels, and normal right-sided invasive hemodynamics. Only observational registry data support this recommendation. Our aim was to test these goals in a large group 1 PAH cohort against long-term survival.

METHODS

We analyzed the PHIRST and TRIUMPH populations (n = 563, age 53.5 ± 14.7 years, female sex 79%). The predictor variables were the treatment goals measured at the end of the placebo-controlled phase (16 and 12 weeks, respectively). The primary outcome was all-cause mortality at the end of follow-up during the open-label extension phase.

RESULTS

There were 73 deaths during median follow of 1072 days (range 27 to 2177). Patients who achieved a functional class I or II had better survival. Both a 6MWD ≥ 380 m and ≥ 440 m were associated with lower mortality, but survival was better in patients able to walk ≥ 440 m. The best long-term survival was achieved with functional class I or II and 6MWD ≥ 440 m. In a subset of the population, cardiac index > 2.5 L/min/m was weakly associated with better survival.

CONCLUSION

WHO functional class I or II, 6MWD ≥ 440 m and CI > 2.5 L/min/m measured 12-16 weeks after the introduction of PAH-targeted therapy are associated with better long-term survival in PAH. Best survival is observed by reaching both the functional class and the 6MWD goals.

摘要

目的

指南建议肺动脉高压 (PAH) 患者达到特定的治疗目标:心功能 I 或 II 级、6 分钟步行距离(6MWD)≥380 至 440m、正常利钠肽水平和正常右侧有创血流动力学。目前仅观察性登记数据支持这一建议。我们的目的是在一个较大的 1 类 PAH 队列中检验这些目标与长期生存之间的关系。

方法

我们分析了 PHIRST 和 TRIUMPH 队列(n=563,年龄 53.5±14.7 岁,女性占 79%)。预测变量为安慰剂对照阶段结束时(分别为第 16 周和第 12 周)测量的治疗目标。主要结局是在开放标签扩展阶段的随访期末全因死亡率。

结果

中位随访 1072 天(范围 27 至 2177 天)期间有 73 例死亡。达到心功能 I 或 II 级的患者生存情况更好。6MWD≥380m 和≥440m 均与较低的死亡率相关,但能行走≥440m 的患者生存情况更好。心功能 I 或 II 级和 6MWD≥440m 时患者长期生存情况最佳。在人群的亚组中,心脏指数(CI)>2.5 L/min/m 与生存情况改善有弱相关性。

结论

PAH 靶向治疗开始后 12-16 周测量的 WHO 心功能 I 或 II 级、6MWD≥440m 和 CI>2.5 L/min/m 与 PAH 患者的长期生存相关。同时达到心功能和 6MWD 目标可获得最佳生存。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验